Микро-РНК как новый биомаркер активности системы цитохрома P-450: значение для прогнозирования антиагрегантного действия ингибиторов P2Y12-рецепторов
________________________________________________
Rytkin E.I., Mirzaev K.B., Bure I.V., Sychev D.A. Micro-RNA as a new biomarker of activity of the cytochrome system P-450: importance for predicting the antiplatelet action of P2Y12 receptor inhibitors. Therapeutic Archive. 2019; 91 (8): 115–117. DOI: 10.26442/00403660.2019.08.000389
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: микро-РНК, биомаркер, персонализация, антиагреганты.
________________________________________________
MicroRNAs are short non-coding RNAs that correlate with the levels of platelet activation which can be utilized as a biomarker when guiding P2Y12 inhibitors therapy. In this literature review, the perspectives of microRNA as a novel biomarker are discussed when guiding P2Y12 inhibitors therapy among the patients with coronary artery disease.
Keywords: microRNA, biomarker, personalized therapy, antiplatelet drugs.
2. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009 Jan 23;136(2):215-33. doi:10.1016/j.cell.2009.01.002
3. Sunderland N, Skroblin P, Barwari T, et al. MicroRNA Biomarkers and Platelet Reactivity The Clot Thickens. Circ Res. 2017;120:418-35. doi: 10.1161/circresaha.116.309303
4. Yu AM, Pan YZ. Noncoding microRNAs: small RNAs play a big role in regulation of ADME? Acta Pharm Sinica B. 2012;2(2):93-101. doi: 10.1016/j.apsb.2012.02.011
5. Nakano M, Nakajima M. Current knowledge of microRNA mediated regulation of drug metabolism in humans. Expert Opin Drug Metabol Toxicol. 2018 May;14(5):493-504. doi: 10.1080/17425255.2018.1472237
6. Rieger JK, Reutter S, Hofmann U, et al. Inflammation-Associated MicroRNA-130b Down-Regulates Cytochrome P450 Activities and Directly Targets CYP2C9. Drug Metabol Disposit. 2015;43(6):884-8. doi: 10.1124/dmd.114.062844
7. Tang QJ, Lin HM, He GD, et al. Plasma miR-142 accounting for the missing heritability of CYP3A4/5 functionality is associated with pharmacokinetics of clopidogrel. Pharmacogenomics. 2016. Sep; 7(14):1503-17. doi: 10.2217/pgs-2016-0027
8. Chen S, Qi X, Chen H, et al. Expression of miRNA 26a in platelets is associated with clopidogrel resistance following coronary stenting 2016. Exper Ther Med. 2016;12:518-24. doi: 10.3892/etm.2016.3278
9. Kondkar AA, Bray MS, Leal SM, et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost. 2010 Feb;8(2):369-78. doi: 10.1111/j.1538-7836.2009.03700.x
10. Shi R, Ge L, Zhou X, et al. Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity 2013. Thromb Res. 2013;131:508-13. doi: 10.1016/j.thromres.2013.02.015
11. Wang Z, Chen M, Zhu L, et al. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015 Mar 19; 11:449-67. doi: 10.2147/TCRM.S80437
12. Carino A, De Rosa S, Sorrentino S, et al. Modulation of Circulating MicroRNAs Levels during the Switch from Clopidogrel to Ticagrelor. Biomed Res Int. 2016. 5. doi: 10.1155/2016/3968206
13. Willeit P, Zampetaki A, Dudek K, et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res. 2013 Feb 15;112(4):595-600. doi: 10.1161/circresaha.111.300539
14. Agarwal V, Bell GW, Nam JW, et al. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015 Aug 12;4. doi: 10.7554/eLife.05005
15. Rytkin E, Mirzaev KB, Grishina EA, et al. Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients? Pharmacogenom Personal Med. 2017 Sep 18;10:243. doi: 10.2147/PGPM.S143250
16. Mirzaev KB, Rytkin E, Ryzhikova KA, et al. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metabol Personal Ther. 2018 Sep 25;33(3);109-18. doi: 10.1515/dmpt-2018-0006
________________________________________________
1. Stakos DA, Gatsiou A, Stamatelopoulos K, et al. Platelet microRNAs: From platelet biology to possible disease biomarkers and therapeutic targets. Platelets. 2013; 24(8):579-89. doi: 10.3109/09537104.2012.724483
2. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009 Jan 23;136(2):215-33. doi:10.1016/j.cell.2009.01.002
3. Sunderland N, Skroblin P, Barwari T, et al. MicroRNA Biomarkers and Platelet Reactivity The Clot Thickens. Circ Res. 2017;120:418-35. doi: 10.1161/circresaha.116.309303
4. Yu AM, Pan YZ. Noncoding microRNAs: small RNAs play a big role in regulation of ADME? Acta Pharm Sinica B. 2012;2(2):93-101. doi: 10.1016/j.apsb.2012.02.011
5. Nakano M, Nakajima M. Current knowledge of microRNA mediated regulation of drug metabolism in humans. Expert Opin Drug Metabol Toxicol. 2018 May;14(5):493-504. doi: 10.1080/17425255.2018.1472237
6. Rieger JK, Reutter S, Hofmann U, et al. Inflammation-Associated MicroRNA-130b Down-Regulates Cytochrome P450 Activities and Directly Targets CYP2C9. Drug Metabol Disposit. 2015;43(6):884-8. doi: 10.1124/dmd.114.062844
7. Tang QJ, Lin HM, He GD, et al. Plasma miR-142 accounting for the missing heritability of CYP3A4/5 functionality is associated with pharmacokinetics of clopidogrel. Pharmacogenomics. 2016. Sep; 7(14):1503-17. doi: 10.2217/pgs-2016-0027
8. Chen S, Qi X, Chen H, et al. Expression of miRNA 26a in platelets is associated with clopidogrel resistance following coronary stenting 2016. Exper Ther Med. 2016;12:518-24. doi: 10.3892/etm.2016.3278
9. Kondkar AA, Bray MS, Leal SM, et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost. 2010 Feb;8(2):369-78. doi: 10.1111/j.1538-7836.2009.03700.x
10. Shi R, Ge L, Zhou X, et al. Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity 2013. Thromb Res. 2013;131:508-13. doi: 10.1016/j.thromres.2013.02.015
11. Wang Z, Chen M, Zhu L, et al. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015 Mar 19; 11:449-67. doi: 10.2147/TCRM.S80437
12. Carino A, De Rosa S, Sorrentino S, et al. Modulation of Circulating MicroRNAs Levels during the Switch from Clopidogrel to Ticagrelor. Biomed Res Int. 2016. 5. doi: 10.1155/2016/3968206
13. Willeit P, Zampetaki A, Dudek K, et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res. 2013 Feb 15;112(4):595-600. doi: 10.1161/circresaha.111.300539
14. Agarwal V, Bell GW, Nam JW, et al. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015 Aug 12;4. doi: 10.7554/eLife.05005
15. Rytkin E, Mirzaev KB, Grishina EA, et al. Do CYP2C19 and ABCB1 gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients? Pharmacogenom Personal Med. 2017 Sep 18;10:243. doi: 10.2147/PGPM.S143250
16. Mirzaev KB, Rytkin E, Ryzhikova KA, et al. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metabol Personal Ther. 2018 Sep 25;33(3);109-18. doi: 10.1515/dmpt-2018-0006
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
________________________________________________
E.I. Rytkin, K.B. Mirzaev, I.V. Bure, D.A. Sychev
Russian Medical Academy of Continuous Professional Education, Moscow, Russia